Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16729887 | 1.00 | LGALS8 (0.30) | LGALS8 | |
| SCHEMBL14478380 | 0.89 | — | — | |
| SCHEMBL19631498 | 0.85 | LGALS8 (0.33) | LGALS8 | |
| SCHEMBL12292292 | 0.84 | LGALS8 (0.33) | LGALS8 | |
| SCHEMBL20334521 | 0.84 | LGALS8 (0.33) | LGALS8 | |
| SCHEMBL13447823 | 0.84 | LGALS8 (0.35) | LGALS8 | |
| SCHEMBL19661469 | 0.84 | LGALS8 (0.33) | LGALS8 | |
| SCHEMBL23417369 | 0.83 | MAPK1 (0.42) | LGALS8 | |
| SCHEMBL22605123 | 0.83 | MAPK1 (0.42) | LGALS8 | |
| SCHEMBL22605122 | 0.83 | MAPK1 (0.42) | LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001835-B2 | Method for the synthesis of a bifunctional complex | NUEVOLUTION A/S (DK) | 2021-05-11 | — | — | US | disclosed |
| US-9725723-B2 | Compositions and methods for modulation of FGFR3 expression | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2017-08-08 | — | — | US | disclosed |
| EP-2336315-B1 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION AS (DK) | 2017-07-19 | — | — | EP | disclosed |
| US-20170015697-A1 | SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE | SANTARIS PHARMA A/S (DK) | 2017-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015697-A1 | SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE | TNFRSF1A, TNFRSF9, CD40 | LGALS8 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.